Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of
patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL).